Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Stock Rated “Moderate Buy” by Sell-Side Analysts

Posted by Logan Wallace on Sep 26th, 2026

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the six brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $46.67.

NBTX has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research report on Friday, July 17th. Guggenheim began coverage on Nanobiotix in a research report on Tuesday, September 15th. They set a “buy” rating and a $64.00 target price for the company. Finally, Leerink Partners lifted their price target on Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research report on Thursday, June 4th.

View Our Latest Analysis on Nanobiotix

Nanobiotix Price Performance

Shares of NBTX opened at $33.31 on Monday. The business’s 50 day moving average is $38.73 and its 200 day moving average is $37.36. Nanobiotix has a 12-month low of $14.78 and a 12-month high of $57.14.

Nanobiotix (NASDAQ:NBTX – Get Free Report) last announced its quarterly earnings data on Tuesday, September 29th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.08. The company had revenue of $3.17 million for the quarter, compared to analysts’ expectations of $1.73 million. As a group, sell-side analysts anticipate that Nanobiotix will post -0.16 earnings per share for the current fiscal year.

About Nanobiotix

(Get Free Report)

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.